341 related articles for article (PubMed ID: 26562543)
1. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A
Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837
[TBL] [Abstract][Full Text] [Related]
3. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
4. GSK-3 inhibitors for Alzheimer's disease.
Avila J; Hernández F
Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
[TBL] [Abstract][Full Text] [Related]
5. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Khan I; Tantray MA; Alam MS; Hamid H
Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
[TBL] [Abstract][Full Text] [Related]
6. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
Liu SN; Shen ZF
Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation.
Bustanji Y; Taha MO; Almasri IM; Al-Ghussein MA; Mohammad MK; Alkhatib HS
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):771-8. PubMed ID: 18720192
[TBL] [Abstract][Full Text] [Related]
8. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
Medina M; Avila J
Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
[TBL] [Abstract][Full Text] [Related]
9. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease.
Noh MY; Chun K; Kang BY; Kim H; Park JS; Lee HC; Kim YH; Ku S; Kim SH
Biochem Biophys Res Commun; 2013 May; 435(2):274-81. PubMed ID: 23632329
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
11. Lithium, a potential protective drug in Alzheimer's disease.
Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J
Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403
[TBL] [Abstract][Full Text] [Related]
12. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
Huang HC; Klein PS
Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
[TBL] [Abstract][Full Text] [Related]
13. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
[TBL] [Abstract][Full Text] [Related]
14. GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future.
Maqbool M; Hoda N
Curr Pharm Des; 2017 Nov; 23(29):4332-4350. PubMed ID: 28714403
[TBL] [Abstract][Full Text] [Related]
15. [GSK-3beta: a central kinase for neurodegenerative diseases?].
Petit-Paitel A
Med Sci (Paris); 2010 May; 26(5):516-21. PubMed ID: 20510151
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
18. Substrate competitive GSK-3 inhibitors - strategy and implications.
Eldar-Finkelman H; Licht-Murava A; Pietrokovski S; Eisenstein M
Biochim Biophys Acta; 2010 Mar; 1804(3):598-603. PubMed ID: 19770076
[TBL] [Abstract][Full Text] [Related]
19. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805
[TBL] [Abstract][Full Text] [Related]
20. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
